Document is current

Article History

Received: 23 September 2024

Accepted: 20 February 2025

First Online: 26 February 2025

Declarations

:

: KGH reports speaker’s honoraria, consulting fees, lecture honoraria and/or study grants from Abbott, Amarin, AstraZeneca, Bayer Healthcare, Biotronik, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Medronic, Pfizer, Portola, Premier Research, Sanofi, SUN Pharma, and W.L. Gore and Associates, all of which were unrelated to this work. ME reports grants from Bayer and fees paid to the Charité from Abbot, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, GSK, Sanofi, Covidien, Novartis and Pfizer, all of which were unrelated to this work. TB reports consulting fees, lecture honoraria and/or study grants from AstraZeneca, Boehringer Ingelheim, Pfizer, GlaxoSmithKline, MSD, Chiesi, Novartis, and Roche all of which were unrelated to this work. JK reports consulting fees and salaries from Ababax.Health, all of which were unrelated to this work. CF is supported by EU, DFG and BMBF. WM reports funding from the European Union, the German Federal Ministry of Education of Research, German Research Council, Michael J. Fox Foundation, Robert Bosch Foundation, Neuroalliance, Lundbeck, Sivantos and Janssen, speaker honoraria from Abbvie, Bayer, BIAL, GlaxoSmithKline, Heel, Licher MT, Roelke Pharma, Takeda and UCB, was invited to Advisory Boards / Consultancies of Abbvie, Aptar Digital Health, Atheneum, Biogen, Kyowa Kirin, and Pfizer. The other authors have reported no potential conflicts of interest.

: In accordance with the Declaration of Helsinki, written informed consent was obtained from all COVIDOM participants. The study has received ethical approval from the Ethics Committee of the Faculty of Medicine at the Christian Albrecht University in Kiel, Germany (reference numbers: Kiel D537/20, also valid for the Berlin site) and from the Ethics Committee of the Institute for Pharmacology and Toxicology of the Julius Maximilians University in Wuerzburg, Germany (236/20_z-am). COVIDOM was registered in the German Registry of Clinical Studies (DRKS00023742) and in ClinicalTrials.gov (NCT04679584).